Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD10 expression in non-small cell lung cancer.

Glen Kristiansen1, Karsten Schlüns, Yu Yongwei

  • 1Institute of Pathology, Charité University Hospital, Berlin, Germany.

Analytical Cellular Pathology : the Journal of the European Society for Analytical Cellular Pathology
|July 18, 2002
PubMed
Summary

CD10 expression was found in 19% of non-small cell lung cancer (NSCLC) cases. This study found no significant association between CD10 levels and NSCLC patient outcomes or characteristics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peer-to-peer validation of Ki-67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2024
Same author

Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.

Cancer medicine·2024
Same author

FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.

Journal of neuropathology and experimental neurology·2024
Same author

Pathology skills lab: use of macroscopic tumor models in pathology teaching.

BMC medical education·2024
Same author

Neuropilin2 in Mesenchymal Stromal Cells as a Potential Novel Therapeutic Target in Myelofibrosis.

Cancers·2024
Same author

Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.

European urology·2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunohistochemistry

Background:

  • CD10 is a cell surface endopeptidase implicated in regulating cell proliferation.
  • Downregulation of CD10 in lung cancer cell lines correlates with increased proliferation.
  • Previous studies suggest CD10 downregulation in lung cancer tissue, hinting at a role in carcinogenesis and potential prognostic value.

Purpose of the Study:

  • To investigate the expression rate of CD10 in a cohort of non-small cell lung cancer (NSCLC) tissues.
  • To evaluate the correlation between CD10 expression and clinicopathological parameters in NSCLC.
  • To determine if CD10 expression serves as a prognostic marker for patient survival in NSCLC.

Main Methods:

  • Immunohistochemical analysis was performed on 114 NSCLC tissue microarrays using a monoclonal CD10 antibody (clone NCL-CD10-270).

Related Experiment Videos

  • CD10 staining was quantified semiquantitatively.
  • Statistical analysis was conducted to assess associations with tumor type, size, grade, nodal status, clinical stage, and survival.

    • Main Results:

    • CD10 expression was detected in 19% of the analyzed NSCLC cases.
    • No statistically significant associations were found between CD10 expression levels and tumor type, size, grade, nodal status, or clinical stage.
    • CD10 expression did not correlate with patient survival time.

    Conclusions:

    • The study indicates that CD10 expression is infrequent in NSCLC.
    • CD10 immunostaining does not appear to be a reliable prognostic marker for NSCLC patients.
    • The diagnostic utility of CD10 immunostaining in NSCLC is considered unlikely based on these findings.